Ribosome Biogenesis Related Genes as Prognostic Genes in Glioma: A Study Based on Transcriptomics and Mendelian Randomization

Abstract

Background: Ribosome biogenesis (RiboSis) is strongly associated with cancer progression, but its regulatory mechanisms in glioma are poorly understood. Therefore, it is of great significance to explore the relationship between ribosome biogenesis and glioma and to search for new prognostic genes for glioma.

Methods: Glioma related data and RBRGs were obtained from public databases and literature. Prognostic genes were obtained by differential expression analysis, Mendelian randomization (MR), as well as Cox and least absolute shrinkage and selection operator regression analysis (LASSO) regression analyses, and prognostic risk models were constructed and verified. The calculation of the risk groups score was the basis for the classification of glioma patients into high risk and low risk groups. Enrichment analysis, immune microenvironment analysis, drug sensitivity analysis and molecular docking were performed.

Results: Seven prognostic genes (NCL, FBLL1, YBEY, TP53, POP5, GNL2, and ZEB1) causally associated with glioma were obtained. The risk model effectively predicted the survival status of glioma patients. Enrichment analysis showed significant differences in pantothenate and CoA biosynthesis, and cardiac muscle contraction between high risk and low risk patients. Plasma B cells , monocytes, and activated natural killer (NK) cells were more abundant in the low risk groups. Conversely, M1/M2 macrophages and memory resting CD4+ T cells were more abundant in the high risk groups. Drug sensitivity analysis demonstrated that entrectinib and NVP-ADW742 exhibited the greatest discrepancy between the high-risk group and the low-risk group.

Conclusion: Seven prognostic genes, namely NCL, FBLL1, YBEY, TP53, POP5, GNL2, and ZEB1, were associated with RiboSis and effectively predicted survival in glioma patients, informing the development of more effective, individualized treatments.